You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Antibody drug conjugates

Teicher, Beverly A.

Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000108
LYMPHOMA: Edited by Bertrand Coiffier and Anne-Sophie Michallet
Abstract

Purpose of review: Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The more than 30-year history of antibody conjugates is marked by hurdles that have been identified and overcome.

Recent findings: Technology is continuing to evolve the protein and small molecule components, and it is likely that soon single-chemical entities will be the norm for antibody drug conjugates. More than 20 antibody conjugates are currently in clinical trials.

Summary: The time has arrived for this technology to become a major contributor to improving treatment for cancer patients.

Author Information

National Cancer Institute, Bethesda, Maryland, USA

Correspondence to Beverly A. Teicher, PhD, Chief, Molecular Pharmacology Branch, National Cancer Institute, RM 4-W602, MSC 9735, 9609 Medical Center Drive, Bethesda, MD 20892, USA. Tel: +1 240 276 5972; fax: +1 240 276 7895; e-mail: Beverly.Teicher@nih.gov, teicherba@mail.nih.gov

© 2014 Lippincott Williams & Wilkins, Inc.